Cardiff Oncology, Inc. (CRDF): Price and Financial Metrics
CRDF Price/Volume Stats
Current price | $5.34 | 52-week high | $6.42 |
Prev. close | $5.75 | 52-week low | $0.94 |
Day low | $5.19 | Volume | 864,400 |
Day high | $5.73 | Avg. volume | 1,667,489 |
50-day MA | $2.88 | Dividend yield | N/A |
200-day MA | $1.82 | Market Cap | 238.58M |
CRDF Stock Price Chart Interactive Chart >
CRDF POWR Grades
- CRDF scores best on the Sentiment dimension, with a Sentiment rank ahead of 94.68% of US stocks.
- The strongest trend for CRDF is in Growth, which has been heading down over the past 26 weeks.
- CRDF ranks lowest in Momentum; there it ranks in the 7th percentile.
CRDF Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CRDF is 0.01 -- better than just 9.09% of US stocks.
- With a price/sales ratio of 148.6, CARDIFF ONCOLOGY INC has a higher such ratio than 98.08% of stocks in our set.
- CRDF's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 9.58% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to CARDIFF ONCOLOGY INC are ALGS, MRUS, DBVT, HYLN, and CRIS.
- CRDF's SEC filings can be seen here. And to visit CARDIFF ONCOLOGY INC's official web site, go to www.cardiffoncology.com.
CRDF Valuation Summary
- In comparison to the median Healthcare stock, CRDF's price/earnings ratio is 105.49% lower, now standing at -1.6.
- Over the past 201 months, CRDF's EV/EBIT ratio has gone up 72.9.
Below are key valuation metrics over time for CRDF.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CRDF | 2023-12-29 | 143.7 | 0.8 | -1.6 | -1.3 |
CRDF | 2023-12-28 | 140.9 | 0.8 | -1.6 | -1.3 |
CRDF | 2023-12-27 | 147.6 | 0.9 | -1.7 | -1.3 |
CRDF | 2023-12-26 | 150.4 | 0.9 | -1.7 | -1.4 |
CRDF | 2023-12-22 | 142.8 | 0.8 | -1.6 | -1.3 |
CRDF | 2023-12-21 | 143.7 | 0.8 | -1.6 | -1.3 |
CRDF Growth Metrics
- The 4 year price growth rate now stands at -98.06%.
- The 3 year cash and equivalents growth rate now stands at 76.98%.
- Its 5 year revenue growth rate is now at -1.51%.
The table below shows CRDF's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 0.391 | -31.82 | -39.473 |
2022-06-30 | 0.384 | -29.799 | -37.815 |
2022-03-31 | 0.361 | -27.405 | -34.129 |
2021-12-31 | 0.359 | -23.04 | -28.315 |
2021-09-30 | 0.345255 | -20.77394 | -25.47011 |
2021-06-30 | 0.395656 | -18.83417 | -23.0537 |
CRDF's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CRDF has a Quality Grade of D, ranking ahead of 16.71% of graded US stocks.
- CRDF's asset turnover comes in at 0.004 -- ranking 418th of 682 Pharmaceutical Products stocks.
- OTIC, AVDL, and CORT are the stocks whose asset turnover ratios are most correlated with CRDF.
The table below shows CRDF's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.004 | 1 | -0.388 |
2021-03-31 | 0.004 | 1 | -0.758 |
2020-12-31 | 0.007 | 1 | 17.949 |
2020-09-30 | 0.014 | 1 | 22.880 |
2020-06-30 | 0.015 | 1 | 50.452 |
2020-03-31 | 0.028 | 1 | -56.954 |
CRDF Price Target
For more insight on analysts targets of CRDF, see our CRDF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $25.33 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Cardiff Oncology, Inc. (CRDF) Company Bio
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CRDF News From Around the Web
Below are the latest news stories about CARDIFF ONCOLOGY INC that investors may wish to consider to help them evaluate CRDF as an investment opportunity.
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare ConferenceCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 35th Annual Piper Sandler Healthcare Conference, which is taking place at the Lotte New York Palace in New York from November 28-30, 2023. |
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business UpdateCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. |
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business UpdateCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on Thursday, November 2 after the close of trading. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning! |
CRDF Price Returns
1-mo | 193.41% |
3-mo | 260.81% |
6-mo | 284.17% |
1-year | 223.64% |
3-year | -41.32% |
5-year | 42.40% |
YTD | 260.81% |
2023 | 5.71% |
2022 | -76.71% |
2021 | -66.59% |
2020 | 1,350.81% |
2019 | -60.63% |
Loading social stream, please wait...